Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP.

Knop J, Spilgies LM, Rufli S, Reinhart R, Vasilikos L, Yabal M, Crowley E, Jost PJ, Marsh RA, Wajant H, Robinson MD, Kaufmann T, Wong WW.

Cell Death Dis. 2019 Sep 20;10(10):700. doi: 10.1038/s41419-019-1938-x.

2.

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.

Jilg S, Hauch RT, Kauschinger J, Buschhorn L, Odinius TO, Dill V, Müller-Thomas C, Herold T, Prodinger PM, Schmidt B, Hempel D, Bassermann F, Peschel C, Götze KS, Höckendorf U, Haferlach T, Jost PJ.

Exp Hematol Oncol. 2019 Apr 16;8:9. doi: 10.1186/s40164-019-0133-1. eCollection 2019.

3.

Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).

Jilg S, Rassner M, Maier J, Waldeck S, Kehl V, Follo M, Philipp U, Sauter A, Specht K, Mitschke J, Lange T, Bauer S, Jost PJ, Peschel C, Duyster J, Gaiser T, Hohenberger P, von Bubnoff N.

Int J Cancer. 2019 Oct 15;145(8):2292-2303. doi: 10.1002/ijc.32282. Epub 2019 Apr 29.

PMID:
30882891
4.

[Kinase inhibitors in oncology : What is new?]

Riedmann K, Bassermann F, Jost PJ.

Internist (Berl). 2019 May;60(5):540-544. doi: 10.1007/s00108-019-0577-8. Review. German.

PMID:
30859279
5.

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Huemer F, Melchardt T, Jansko B, Wahida A, Jilg S, Jost PJ, Klieser E, Steiger K, Magnes T, Pleyer L, Greil-Ressler S, Rass C, Greil R, Egle A.

Eur J Haematol. 2019 May;102(5):437-441. doi: 10.1111/ejh.13218. Epub 2019 Feb 28.

PMID:
30725494
6.

A step towards valid detection and quantification of lung cancer volume in experimental mice with contrast agent-based X-ray microtomography.

Bidola P, Martins de Souza E Silva J, Achterhold K, Munkhbaatar E, Jost PJ, Meinhardt AL, Taphorn K, Zdora MC, Pfeiffer F, Herzen J.

Sci Rep. 2019 Feb 4;9(1):1325. doi: 10.1038/s41598-018-37394-w.

7.

XIAP deficiency in hematopoietic recipient cells drives donor T-cell activation and GvHD in mice.

Müller N, Fischer JC, Yabal M, Haas T, Poeck H, Jost PJ.

Eur J Immunol. 2019 Mar;49(3):504-507. doi: 10.1002/eji.201847818. Epub 2019 Jan 3.

PMID:
30585320
8.

Necroinflammation emerges as a key regulator of hematopoiesis in health and disease.

Jost PJ, Höckendorf U.

Cell Death Differ. 2019 Jan;26(1):53-67. doi: 10.1038/s41418-018-0194-4. Epub 2018 Sep 21.

PMID:
30242210
9.

Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft.

Moog P, Jost PJ, Büttner-Herold M.

BMC Nephrol. 2018 May 3;19(1):106. doi: 10.1186/s12882-018-0904-7.

10.

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.

Reidel V, Kauschinger J, Hauch RT, Müller-Thomas C, Nadarajah N, Burgkart R, Schmidt B, Hempel D, Jacob A, Slotta-Huspenina J, Höckendorf U, Peschel C, Kern W, Haferlach T, Götze KS, Jilg S, Jost PJ.

Oncotarget. 2018 Apr 3;9(25):17270-17281. doi: 10.18632/oncotarget.24775. eCollection 2018 Apr 3.

11.

Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.

Rinaldetti S, Pfirrmann M, Manz K, Guilhot J, Dietz C, Panagiotidis P, Spiess B, Seifarth W, Fabarius A, Müller M, Pagoni M, Dimou M, Dengler J, Waller CF, Brümmendorf TH, Herbst R, Burchert A, Janβen C, Goebeler ME, Jost PJ, Hanzel S, Schafhausen P, Prange-Krex G, Illmer T, Janzen V, Klausmann M, Eckert R, Büschel G, Kiani A, Hofmann WK, Mahon FX, Saussele S.

Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):266-271. doi: 10.1016/j.clml.2018.02.004. Epub 2018 Feb 8.

12.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

13.

A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development.

Boege Y, Malehmir M, Healy ME, Bettermann K, Lorentzen A, Vucur M, Ahuja AK, Böhm F, Mertens JC, Shimizu Y, Frick L, Remouchamps C, Mutreja K, Kähne T, Sundaravinayagam D, Wolf MJ, Rehrauer H, Koppe C, Speicher T, Padrissa-Altés S, Maire R, Schattenberg JM, Jeong JS, Liu L, Zwirner S, Boger R, Hüser N, Davis RJ, Müllhaupt B, Moch H, Schulze-Bergkamen H, Clavien PA, Werner S, Borsig L, Luther SA, Jost PJ, Weinlich R, Unger K, Behrens A, Hillert L, Dillon C, Di Virgilio M, Wallach D, Dejardin E, Zender L, Naumann M, Walczak H, Green DR, Lopes M, Lavrik I, Luedde T, Heikenwalder M, Weber A.

Cancer Cell. 2017 Sep 11;32(3):342-359.e10. doi: 10.1016/j.ccell.2017.08.010.

14.

XIAP Loss Triggers RIPK3- and Caspase-8-Driven IL-1β Activation and Cell Death as a Consequence of TLR-MyD88-Induced cIAP1-TRAF2 Degradation.

Lawlor KE, Feltham R, Yabal M, Conos SA, Chen KW, Ziehe S, Graß C, Zhan Y, Nguyen TA, Hall C, Vince AJ, Chatfield SM, D'Silva DB, Pang KC, Schroder K, Silke J, Vaux DL, Jost PJ, Vince JE.

Cell Rep. 2017 Jul 18;20(3):668-682. doi: 10.1016/j.celrep.2017.06.073.

15.

Universal Genomic Testing: The next step in oncological decision-making or a dead end street?

Holch JW, Metzeler KH, Jung A, Riedmann K, Jost PJ, Weichert W, Kirchner T, Heinemann V, Westphalen CB.

Eur J Cancer. 2017 Sep;82:72-79. doi: 10.1016/j.ejca.2017.05.034. Epub 2017 Jul 10.

PMID:
28648701
16.

Survival control of malignant lymphocytes by anti-apoptotic MCL-1.

Fernández-Marrero Y, Spinner S, Kaufmann T, Jost PJ.

Leukemia. 2016 Nov;30(11):2152-2159. doi: 10.1038/leu.2016.213. Epub 2016 Aug 1. Review.

PMID:
27479182
17.

Loss of XIAP facilitates switch to TNFα-induced necroptosis in mouse neutrophils.

Wicki S, Gurzeler U, Wei-Lynn Wong W, Jost PJ, Bachmann D, Kaufmann T.

Cell Death Dis. 2016 Oct 13;7(10):e2422. doi: 10.1038/cddis.2016.311.

18.

Killing AML: RIPK3 leads the way.

Höckendorf U, Yabal M, Jost PJ.

Cell Cycle. 2017 Jan 2;16(1):3-4. doi: 10.1080/15384101.2016.1232069. Epub 2016 Oct 11. No abstract available.

19.

RIPK3-dependent cell death and inflammasome activation in FLT3-ITD expressing LICs.

Höckendorf U, Yabal M, Jost PJ.

Oncotarget. 2016 Sep 6;7(36):57483-57484. doi: 10.18632/oncotarget.11195. No abstract available.

20.

RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.

Höckendorf U, Yabal M, Herold T, Munkhbaatar E, Rott S, Jilg S, Kauschinger J, Magnani G, Reisinger F, Heuser M, Kreipe H, Sotlar K, Engleitner T, Rad R, Weichert W, Peschel C, Ruland J, Heikenwalder M, Spiekermann K, Slotta-Huspenina J, Groß O, Jost PJ.

Cancer Cell. 2016 Jul 11;30(1):75-91. doi: 10.1016/j.ccell.2016.06.002.

21.

USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma.

Engel K, Rudelius M, Slawska J, Jacobs L, Ahangarian Abhari B, Altmann B, Kurutz J, Rathakrishnan A, Fernández-Sáiz V, Brunner A, Targosz BS, Loewecke F, Gloeckner CJ, Ueffing M, Fulda S, Pfreundschuh M, Trümper L, Klapper W, Keller U, Jost PJ, Rosenwald A, Peschel C, Bassermann F.

EMBO Mol Med. 2016 Aug 1;8(8):851-62. doi: 10.15252/emmm.201506047. Print 2016 Aug.

22.

Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.

Spinner S, Crispatzu G, Yi JH, Munkhbaatar E, Mayer P, Höckendorf U, Müller N, Li Z, Schader T, Bendz H, Hartmann S, Yabal M, Pechloff K, Heikenwalder M, Kelly GL, Strasser A, Peschel C, Hansmann ML, Ruland J, Keller U, Newrzela S, Herling M, Jost PJ.

Leukemia. 2016 Jul;30(7):1520-30. doi: 10.1038/leu.2016.49. Epub 2016 Mar 8.

PMID:
27055871
23.

CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling.

Hrdinka M, Fiil BK, Zucca M, Leske D, Bagola K, Yabal M, Elliott PR, Damgaard RB, Komander D, Jost PJ, Gyrd-Hansen M.

Cell Rep. 2016 Mar 29;14(12):2846-58. doi: 10.1016/j.celrep.2016.02.062. Epub 2016 Mar 17.

24.

Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.

Jilg S, Reidel V, Müller-Thomas C, König J, Schauwecker J, Höckendorf U, Huberle C, Gorka O, Schmidt B, Burgkart R, Ruland J, Kolb HJ, Peschel C, Oostendorp RA, Götze KS, Jost PJ.

Leukemia. 2016 Jan;30(1):112-23. doi: 10.1038/leu.2015.179. Epub 2015 Jul 8.

PMID:
26153654
25.

XIAP as a regulator of inflammatory cell death: the TNF and RIP3 angle.

Yabal M, Jost PJ.

Mol Cell Oncol. 2014 Oct 29;2(1):e964622. doi: 10.4161/23723548.2014.964622. eCollection 2015 Jan-Mar.

26.

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137. Epub 2014 Sep 19. Review.

27.

XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation.

Yabal M, Müller N, Adler H, Knies N, Groß CJ, Damgaard RB, Kanegane H, Ringelhan M, Kaufmann T, Heikenwälder M, Strasser A, Groß O, Ruland J, Peschel C, Gyrd-Hansen M, Jost PJ.

Cell Rep. 2014 Jun 26;7(6):1796-808. doi: 10.1016/j.celrep.2014.05.008. Epub 2014 May 29.

28.

The acute transcriptomic and proteomic response of HC-04 hepatoma cells to hepatocyte growth factor and its implications for Plasmodium falciparum sporozoite invasion.

Tao D, King JG, Tweedell RE, Jost PJ, Boddey JA, Dinglasan RR.

Mol Cell Proteomics. 2014 May;13(5):1153-64. doi: 10.1074/mcp.M113.035584. Epub 2014 Feb 16.

29.

cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner.

Wong WW, Vince JE, Lalaoui N, Lawlor KE, Chau D, Bankovacki A, Anderton H, Metcalf D, O'Reilly L, Jost PJ, Murphy JM, Alexander WS, Strasser A, Vaux DL, Silke J.

Blood. 2014 Apr 17;123(16):2562-72. doi: 10.1182/blood-2013-06-510743. Epub 2014 Feb 4.

30.

Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature.

Schweneker K, Clemm C, Brügel M, Souvatzoglou M, Hermisson M, Schmidt-Graf F, Zimmer C, Peschel C, Jost PJ.

Exp Hematol Oncol. 2014 Dec 17;3:29. doi: 10.1186/2162-3619-3-29. eCollection 2014.

31.

Evidence of an autoregulatory mechanism of regional bone blood flow at hypotension.

Vogt S, Venjakob AJ, Stöckl K, Tischer T, Jost PJ, Imhoff AB, Thein E, Anetzberger H.

Arch Orthop Trauma Surg. 2013 Sep;133(9):1233-41. doi: 10.1007/s00402-013-1801-y. Epub 2013 Jul 6.

PMID:
23832129
32.

Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling.

Damgaard RB, Fiil BK, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S, Jost PJ, Ehl S, Mailand N, Gyrd-Hansen M.

EMBO Mol Med. 2013 Aug;5(8):1278-95. doi: 10.1002/emmm.201303090. Epub 2013 Jul 1.

33.

Local cooling reduces regional bone blood flow.

Venjakob AJ, Vogt S, Stöckl K, Tischer T, Jost PJ, Thein E, Imhoff AB, Anetzberger H.

J Orthop Res. 2013 Nov;31(11):1820-7. doi: 10.1002/jor.22417. Epub 2013 Jun 28.

34.

The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity.

Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, Rieser E, Rickard JA, Bankovacki A, Peschel C, Ruland J, Bekker-Jensen S, Mailand N, Kaufmann T, Strasser A, Walczak H, Silke J, Jost PJ, Gyrd-Hansen M.

Mol Cell. 2012 Jun 29;46(6):746-58. doi: 10.1016/j.molcel.2012.04.014. Epub 2012 May 17.

35.

Fas death receptor signalling: roles of Bid and XIAP.

Kaufmann T, Strasser A, Jost PJ.

Cell Death Differ. 2012 Jan;19(1):42-50. doi: 10.1038/cdd.2011.121. Epub 2011 Sep 30. Review.

36.

Mcl-1 is essential for germinal center formation and B cell memory.

Vikstrom I, Carotta S, Lüthje K, Peperzak V, Jost PJ, Glaser S, Busslinger M, Bouillet P, Strasser A, Nutt SL, Tarlinton DM.

Science. 2010 Nov 19;330(6007):1095-9. doi: 10.1126/science.1191793. Epub 2010 Oct 7.

37.

Cancer caused by too much apoptosis--an intriguing contradiction?

Jost PJ, Kaufmann T.

Hepatology. 2010 Apr;51(4):1110-2. doi: 10.1002/hep.23514. No abstract available.

PMID:
20162729
38.

XIAP discriminates between type I and type II FAS-induced apoptosis.

Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, Strasser A, Kaufmann T.

Nature. 2009 Aug 20;460(7258):1035-9. doi: 10.1038/nature08229. Epub 2009 Jul 22.

39.

International EMBO Workshop on 'Model Organisms in Cell Death Research', Obergurgl (Austria).

Bianchi K, Jost PJ, Kaufmann T, Rutkowski R.

Cell Death Differ. 2009 Aug;16(8):1180-3. doi: 10.1038/cdd.2009.60. No abstract available.

40.

The many roles of FAS receptor signaling in the immune system.

Strasser A, Jost PJ, Nagata S.

Immunity. 2009 Feb 20;30(2):180-92. doi: 10.1016/j.immuni.2009.01.001. Review.

41.

Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim.

Kaufmann T, Jost PJ, Pellegrini M, Puthalakath H, Gugasyan R, Gerondakis S, Cretney E, Smyth MJ, Silke J, Hakem R, Bouillet P, Mak TW, Dixit VM, Strasser A.

Immunity. 2009 Jan 16;30(1):56-66. doi: 10.1016/j.immuni.2008.10.017.

42.

Bcl10/Malt1 signaling is essential for TCR-induced NF-kappaB activation in thymocytes but dispensable for positive or negative selection.

Jost PJ, Weiss S, Ferch U, Gross O, Mak TW, Peschel C, Ruland J.

J Immunol. 2007 Jan 15;178(2):953-60.

43.
44.

Very severe iron-deficiency anemia in a patient with celiac disease and bulimia nervosa: a case report.

Jost PJ, Stengel SM, Huber W, Sarbia M, Peschel C, Duyster J.

Int J Hematol. 2005 Nov;82(4):310-1.

PMID:
16298820
45.

Report of a male patient with brain metastases from breast cancer.

Nieder C, Jost PJ, Grosu AL, Peschel C, Molls M.

Breast. 2003 Oct;12(5):345-7.

PMID:
14659151
46.

A novel peptide, THALWHT, for the targeting of human airway epithelia.

Jost PJ, Harbottle RP, Knight A, Miller AD, Coutelle C, Schneider H.

FEBS Lett. 2001 Feb 2;489(2-3):263-9.

Supplemental Content

Support Center